UK markets open in 4 hours 59 minutes

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
17.39+0.14 (+0.81%)
At close: 4:00PM EDT

17.39 0.00 (0.00%)
After hours: 5:02PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close17.25
Open17.13
Bid17.33 x 900
Ask17.35 x 900
Day's range16.90 - 17.40
52-week range9.01 - 21.30
Volume414,580
Avg. volume723,208
Market cap815.888M
Beta (5Y monthly)0.72
PE ratio (TTM)N/A
EPS (TTM)-3.99
Earnings date25 Feb 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.25
  • Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain
    Business Wire

    Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) ("Roclanda®") has received marketing authorisation from the Medicines and Healthcare Products Regulatory Agency ("MHRA") in Great Britain. Roclanda® is indicated for the reduction of elevated intraocular pressure ("IOP") in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction (reference Great Britain Summary of Product Characteristics).

  • Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
    Business Wire

    Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 12:45 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.

  • Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
    Business Wire

    Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in eLife, a science journal, entitled, "Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis." This paper evaluates the treatment effect of netarsudil, marketed as Rhopressa® (netarsudil ophthalmic solution) 0.02% in the United States, on steroid-induced ocular hypertension in a mouse model and steroid-induced glaucoma in humans.